常山药业(300255.SZ)发布前三季度业绩，归母净亏损4481.74万元

Core Viewpoint - Changshan Pharmaceutical (300255.SZ) reported a decline in revenue and an increase in net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's revenue for the first three quarters was 681 million yuan, representing a year-on-year decrease of 13.11% [1] - The net loss attributable to shareholders of the listed company was 44.82 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 47.69 million yuan [1] - The basic loss per share was 0.05 yuan [1]